Scientists at a biotech company have used gene editing to produce a hypoallergenic beagle named Bailey, and the work is being described as the first time the technique has been successful in dogs. The company, Kindred Companion Sciences, created Bailey and her twin Alfie using CRISPR, the Nobel Prize-winning gene-editing technique. The result is being sold as a breakthrough. It also shows how far biotech firms will go to redesign living creatures for the comfort of people who can pay for the science.
Matt Walker, a geneticist, said, “The feeling right now is sort of a mix of relief and awe and gratitude that it worked.” Walker said he couldn't pet a dog without sneezing before the work was done. Now he can feed Bailey spoons of peanut butter while she lies on his lap and play fetch with her in Central Park. His allergies didn't go away, but Bailey's saliva and hair no longer contain a key allergy-causing protein. Walker said all dogs have the same allergy-causing gene that was edited in Alfie and Bailey, and Kindred Companion Sciences hopes to test the technique on other dogs and service animals to see if it can breed an allergy-free line of pups beyond beagles.
Who Gets the Benefit
The research, published Wednesday in the CRISPR Journal, started in the lab when scientists edited the genetic code inside dog skin cells, switching off the main gene responsible for producing allergy-causing proteins. They then transferred the edited genetic code into eggs that went into a beagle surrogate that gave birth to two healthy female pups in September 2024. Scientists tested their saliva and fur and didn't find signs of the allergy-causing protein. The machinery of biotech did what it always does: takes a living body, edits it, tests it, and calls the result progress.
They also performed an allergy test, pricking Walker's skin with extracts from Alfie and Bailey's saliva and dander. His skin reacted to samples from a poodle and goldendoodle, but not from the beagles. Bailey lives with Walker in New York, and Alfie lives in Florida with another Kindred scientist. Walker has had Bailey for a little over a year and says she's become a member of the family. The family, in this case, is built through laboratory intervention and corporate ownership of the process.
What the Lab Says
Dogs that shed less, like poodles, are often thought of as hypoallergenic, but they still produce allergy-causing proteins in their saliva, hair and dander. Researchers have tried to create hypoallergenic pets before, mostly using cloning, but that led to sicker pups that were too genetically similar. Two years ago, researchers used CRISPR to reduce levels of an allergy-causing protein in a cat named Alsik, but it isn't yet clear whether that technique is safe to be tested on other cats. The pattern is familiar. First the market wants a fix, then science is pushed to deliver one, and the living subject becomes the test site.
Bioethicist Arthur Caplan of New York University's Grossman School of Medicine said, “It opens the door to a lot more people being able to own pets. On the negative side, it may discourage people from trying to use strays and unwanted animals that are not engineered to be allergy-free.” That warning lands where the glossy biotech pitch does not. The promise is access. The cost is another nudge toward treating animals as products, while strays and unwanted animals remain outside the frame.
Dr. Jeff SoRelle, a pathologist at University of Texas Southwestern Medical Center, said future research should test the gene-edited hypoallergenic dogs on more people with pet allergies to be sure they can soothe symptoms across a broader swath of the human population. SoRelle, who had no role in the study, said, “we don’t exactly know just how effective or broadly useful this could be for stopping dog allergy in humans.” Even the experts admit the limits. The apparatus wants certainty, but the body doesn’t always cooperate.
Walker said the edit made to the dogs' genes is rare but does occur naturally in some dogs, so he said it's unlikely to have any negative effects on the pups. He said it will still be important to monitor them at routine vet visits and make sure they stay healthy. Despite being a lifelong dog lover, his allergies kept him away from pups growing up. Even breeds that were supposed to be more hypoallergenic, like his family's goldendoodle, gave him itchy eyes and painful rashes. But he and Bailey can play tug-of-war together in his living room, and she snuggles at his feet to comfort him when he's sick. Walker said, “It feels just amazing to get to have a dog.”
That last line says plenty. A biotech company edits dogs so one man can stop sneezing around them, while the broader questions about who gets to shape life, who gets used as the test case, and who gets left with the consequences sit quietly in the background, waiting for the next round of manufactured consent.